Compounded Semaglutide in 2026: Legal Status, 503A vs 503B, and What Patients Need to Know

If you've been following the GLP-1 medication space over the past two years, you've watched a dramatic regulatory saga unfold in real time. Compounded semaglutide went from a legal and widely available option — enabled by a genuine drug shortage — to a contested gray zone where the rules changed every few months. As of April 2026, the FDA has issued its clearest guidance yet. Here's what patients and prescribers actually need to know.

What Is Compounded Semaglutide?

Semaglutide is the active ingredient in Ozempic (for type 2 diabetes) and Wegovy (for weight management), both manufactured by Novo Nordisk. Compounded semaglutide is a version produced by a compounding pharmacy — a facility that mixes, prepares, or alters pharmaceutical ingredients, typically to meet needs that commercially available products can't.

Compounding is a legitimate and federally recognized practice in the U.S. It allows pharmacies to adjust doses, remove allergens, change formulations, or provide drugs that are in shortage. Compounded medications are not FDA-approved products — they are exempt from the standard approval process under specific legal conditions.

During 2022–2025, Ozempic and Wegovy faced severe supply shortages. That shortage window created a legal pathway for compounding pharmacies to produce semaglutide at scale. At peak, hundreds of compounding operations were dispensing GLP-1 medications to hundreds of thousands of patients. Then the shortage ended.

The Legal Framework: 503A vs 503B

To understand the current rules, you need to know the two main categories of compounding under the Food, Drug, and Cosmetic Act:

503A — Traditional Compounding Pharmacies

Section 503A covers state-licensed compounding pharmacies operating under state pharmacy board oversight. These pharmacies:

• Compound medications based on individual patient prescriptions
• Are regulated primarily by state pharmacy boards (not FDA-inspected)
• Can compound drugs on the shortage list or with a clinical rationale for a "significant difference" from the commercial product
• Cannot manufacture large batches in advance — products must be patient-specific

503B — FDA-Registered Outsourcing Facilities

Section 503B covers larger-scale "outsourcing facilities" that register with the FDA. These facilities:

• Are FDA-registered and subject to FDA inspection
• Must follow current Good Manufacturing Practices (cGMP)
• Can produce larger batches without patient-specific prescriptions
• May only compound bulk substances that appear on the FDA's 503B bulks list or drugs that are on the official FDA drug shortage list

The critical point: semaglutide was only legally compoundable at scale because it was on the FDA drug shortage list. Once that shortage was resolved, the legal foundation for 503B compounding largely disappeared.

The Timeline: From Shortage to Enforcement

The Shortage Window (2022–Early 2025)

Ozempic and Wegovy appeared on the FDA drug shortage list due to unprecedented demand outpacing Novo Nordisk's manufacturing capacity. This triggered the shortage-based compounding exemption. Both 503A pharmacies and 503B outsourcing facilities began compounding semaglutide legally.

Shortage Resolution and Wind-Down (Early–Mid 2025)

The FDA declared the semaglutide shortage resolved in February 2025. Under federal compounding law, this triggered a phased enforcement wind-down:

• 503A pharmacies: The period of enforcement discretion for patient-specific compounding ended shortly after the shortage resolution.
• 503B outsourcing facilities: FDA extended enforcement discretion until May 22, 2025, giving larger facilities additional time to wind down operations.

Litigation and Continued Access (2025–2026)

The compounding industry pushed back hard. Compounding trade organizations and individual pharmacies filed lawsuits challenging the FDA's timeline and authority. Several court injunctions allowed some 503B facilities to continue operating while litigation proceeded. This created a patchwork legal environment where access varied depending on the specific pharmacy and jurisdiction.

April 2026 FDA Clarification

On April 1, 2026, the FDA issued updated guidance clarifying what compounders must do to qualify for the statutory exemptions under Sections 503A and 503B. The key clarification addressed the "essentially a copy" standard:

• A compounded drug qualifies as "essentially a copy" if it contains the same active ingredient at the same, similar, or easily substitutable strength and uses the same route of administration
• Adding ingredients like vitamin B12 or L-carnitine does not remove a product from "essentially a copy" status if the semaglutide dose is within 10% of a commercial product
• 503A pharmacies may compound up to four prescriptions per month for a given GLP-1 product without enforcement action — but must have prescriber documentation of a "significant difference" that the compounded product provides for that specific patient
• 503B outsourcing facilities cannot compound semaglutide or tirzepatide as essentially-a-copy products because neither drug appears on the 503B bulks list or the current shortage list

What Is Still Legal in 2026?

The current legal landscape, as of April 2026:

503A Compounding (Still Available)

Traditional compounding pharmacies can still legally produce compounded semaglutide under 503A if:

1. A licensed prescriber writes a patient-specific prescription
2. The prescriber documents a clinical reason the compounded version provides a "significant difference" from the commercial product (e.g., a documented intolerance to an excipient in Ozempic/Wegovy, a need for a non-standard dose, or another individualized clinical rationale)
3. The pharmacy stays within the four-prescriptions-per-month threshold to avoid enforcement scrutiny

Quality standards in 503A pharmacies vary considerably since FDA does not inspect them. State pharmacy board oversight varies by state.

503B Compounding (Largely Foreclosed)

For outsourcing facilities, the legal pathway is essentially closed for standard compounded semaglutide. Some facilities continue operating under court-issued injunctions protecting them during ongoing litigation. These injunctions are not permanent — they can be dissolved at any time if courts rule against compounders.

The Gray Zone: Peptide Clinics and Telehealth

Many telehealth platforms and peptide clinics that dispensed compounded GLP-1s have transitioned to one of three models:

• Prescribing FDA-approved Ozempic/Wegovy through insurance or manufacturer savings programs
• Partnering with 503A pharmacies that meet the "significant difference" documentation requirement
• Exiting the compounded GLP-1 market entirely

Some continue dispensing through legally questionable channels. This is where patient safety risk is highest.

How to Evaluate a Compounding Pharmacy for Semaglutide

If you are accessing compounded semaglutide through a legitimate 503A pharmacy, here are the markers of a quality operation:

Verification Steps

• State pharmacy license: Verify the pharmacy is licensed in your state. The NABP (National Association of Boards of Pharmacy) maintains a database at nabp.pharmacy.
• PCAB accreditation: The Pharmacy Compounding Accreditation Board provides voluntary accreditation — a quality indicator beyond basic licensure.
• Prescription requirement: Any legitimate compounder requires a valid prescription from a licensed prescriber. No prescription = no legitimate compounding.
• Certificate of Analysis (CoA): Reputable compounders provide third-party batch testing documentation confirming potency, purity, and sterility. Ask for it.
• Sterility compliance: Injectable compounds must be prepared in a USP <797> compliant clean room environment. Ask directly about their sterile compounding certification.
• No novel ingredients without clinical rationale: Some compounders add "enhancers" like B12, L-carnitine, or NAD+. While some may be legitimate, additives that serve primarily marketing purposes rather than documented clinical need are a yellow flag.

Red Flags to Avoid

• Selling semaglutide without a prescription
• Shipping across state lines without prescriber involvement
• No transparency about the compounding facility's identity
• Prices dramatically below market without explanation
• Marketing claims that suggest their compound is equivalent or superior to Ozempic/Wegovy without clinical evidence
• No Certificate of Analysis available on request

Safety Considerations: What Patients Should Know

Compounded semaglutide carries specific safety considerations that commercially manufactured products don't:

Potency Variation

FDA-approved drugs must meet strict potency specifications. Compounded drugs are not held to the same federal standards. Studies and FDA testing of compounded GLP-1 products have found potency variation — some batches contained significantly more or less active ingredient than labeled. Under-dosing reduces efficacy; overdosing increases side effect risk including nausea, vomiting, and hypoglycemia.

Sterility

Improperly prepared injectables pose infection risk. The FDA has received adverse event reports from patients using compounded GLP-1s, including reports of hospitalizations. Most of these were linked to facilities with poor sterile compounding practices.

Unlabeled Ingredients

Some compounded semaglutide products have contained undisclosed ingredients or incorrect salt forms (e.g., semaglutide sodium or acetate rather than the semaglutide used in approved products). These variants have not been studied in clinical trials and their safety and bioequivalence are unknown.

The Cost Question: Why Patients Turn to Compounded GLP-1s

The practical reality is that Ozempic and Wegovy have list prices of $900–$1,400 per month in the U.S. without insurance. Compounded semaglutide has been available for $150–$400 per month — a difference that, for uninsured patients, is determinative.

As the compounding market tightens, patients who cannot afford brand-name GLP-1s have limited alternatives:

• Novo Nordisk savings programs: NovoCare offers eligible uninsured patients Ozempic for $99/month and Wegovy coupons reducing cost to $0 for qualifying patients.
• International mail-order pharmacies: Legal in some circumstances, but involves navigating import rules and provider documentation requirements.
• Generic entry: No generic semaglutide exists yet; Novo Nordisk's patents run through the late 2020s and early 2030s.
• Oral orforglipron (Foundayo): The newly FDA-approved oral GLP-1 may offer a different access pathway once it reaches market at scale.

The Bottom Line for Patients in 2026

Compounded semaglutide exists in a narrowed but not fully closed legal window. Through legitimate 503A pharmacies with proper prescriber involvement, patient-specific clinical rationale, and quality compounding standards, it remains a lawful option for some patients. The volume of large-scale 503B compounding that characterized 2023–2024 has largely ended or is operating on borrowed legal time.

For patients currently using compounded semaglutide: verify your pharmacy's credentials, ask for a Certificate of Analysis, and confirm your prescriber has documented the clinical rationale for your compounded prescription. For patients exploring options: the brand-name savings programs are worth investigating before assuming compounding is the only affordable path.

The regulatory situation will continue to evolve. Court decisions in ongoing litigation, potential future shortages, and FDA rulemaking could all shift the landscape again. Staying informed — and working with a knowledgeable prescriber — remains the most reliable guide through it.